Latham & Watkins advises e.l.f. Beauty in its acquisition of Naturium. e.l.f. Beauty (NYSE: ELF) has announced it has signed a definitive agreement to acquire Naturium,...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises MindMed in growth financing with K2 HealthVentures. Mind Medicine Inc. (MindMed), a clinical stage biopharmaceutical company developing novel product candidates to treat...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advises on Heron Therapeutics’ working capital credit facility. Heron Therapeutics, Inc. (Heron), a commercial-stage biotechnology company focused on improving the lives of patients...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Herzog Fox & Neeman and Latham & Watkins LLP are advising ODDITY Tech Ltd., while Davis Polk & Wardwell and Goldfarb Gross Seligman & Co. are...
You must be a Standard 1 Year member to access this content.
Sheppard Mullin represented RadNet, and Latham & Watkins represented the underwriters. RadNet, Inc. (NASDAQ: RDNT) has announced the closing of its underwritten public offering of 8,711,250 shares...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Advestra and Latham & Watkins advise Ironwood. Homburger AG serves as legal and tax advisor to VectivBio on the transaction. Goodwin advises Centerview Partners. VectivBio Holding...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
You must be a Standard 1 Year member to access this content.
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
